A prognostic 11-DNA methylation signature for lung squamous cell carcinoma

Lung cancer is the most frequent malignancy and the leading cause of cancer death worldwide (1) Lung squamous cell carcinoma (LUSC) is the second frequent subtype of lung cancer, accounts for approximately 30% (2,3). Although the progress has been made in early diagnosis and therapy, the 5-year survival of LUSC patients remains dissatisfactory. There is still a lack of effective biomarkers for identifying patients with high risk of recurrence and poor prognosis. Hence, there is an urgent need to find effective biomarkers to improve the ability of clinical prognosis prediction and make individualized therapy decisions